Does Ribociclib Still Help After 3 Years? The NATALEE Trial’s 4-Year Follow-Up Answers

n

For patients with hormone receptor–positive, HER2-negative early breast cancer (HR+/ERBB2– EBC), preventing recurrence is one of the most important goals after surgery. Even with standard endocrine therapy, the risk of cancer returning can continue for many years.

The NATALEE trial was designed to test whether adding the CDK4/6 inhibitor Ribociclib to a nonsteroidal aromatase inhibitor (NSAI) could reduce the risk of recurrence in early breast cancer. Earlier analyses already showed benefit. Now, the 4-year follow-up update provides an important answer to a key question:

Does ribociclib continue to help even after the 3-year treatment period ends?

According to the updated data, the answer appears to be yes.

Why Recurrence Prevention Matters in HR+/HER2– Early Breast Cancer

HR+/HER2– early breast cancer is the most common subtype of breast cancer. Although outcomes are generally favorable, recurrence remains a major concern.

Researchers noted that:

• Around 50% of recurrences occur within the first 5 years.
• Recurrence risk can continue even beyond 20 years.
• Many recurrences are distant (metastatic) and incurable.

Because of this, improving invasive disease-free survival (iDFS) and distant disease-free survival (dDFS) is considered a critical unmet need.

What Is the NATALEE Trial?

The NATALEE trial (New Adjuvant Trial With Ribociclib) was a large, randomized phase 3 study evaluating adjuvant ribociclib in combination with endocrine therapy.

Who Participated?

• 5,101 patients
• Median age: 52 years
• 99.6% women (20 men included)
• HR-positive, ERBB2-negative early breast cancer
• At risk of recurrence

Patients were randomized 1:1 to:

Arm A (Experimental):

• Ribociclib 400 mg daily (for 36 months)
• NSAI (letrozole 2.5 mg or anastrozole 1 mg daily for 60 months)

Arm B (Control):

• NSAI alone for 60 months

Premenopausal women and men also received goserelin for ovarian suppression.

Importantly, ribociclib was given for 3 years, while endocrine therapy continued for 5 years.

What Did the 4-Year Follow-Up Show?

The updated analysis occurred after all participants had completed or discontinued ribociclib treatment. The median follow-up was 44.2 months, indicating patients were followed beyond the 3-year ribociclib treatment period.

Invasive Disease-Free Survival (iDFS)

At 4 years:

• iDFS rate with ribociclib + NSAI: 88.5%
• iDFS rate with NSAI alone: 83.6%

This represents an absolute improvement of 4.9 percentage points.

The hazard ratio (HR) was 0.72, indicating a 28% reduction in the risk of invasive disease recurrence.

Importantly, the benefit:

• Continued beyond the 3-year treatment period.
• Increased from year 3 to year 4.

This suggests the protective effect may persist even after stopping ribociclib.

Distant Disease-Free Survival (dDFS)

Distant recurrence is especially concerning because metastatic disease is not curable.

The 4-year update showed:

• Consistent improvement in distant disease-free survival.
• Hazard ratio is also 0.72.

This indicates fewer distant recurrences in the ribociclib group.

Other Recurrence Measures

Additional outcomes also favored ribociclib:

• Recurrence-Free Survival (RFS): HR 0.70
• Distant Recurrence-Free Survival (dRFS): HR 0.71

Across multiple recurrence risk measures, ribociclib continued to demonstrate benefit.

Were the Benefits Consistent Across Subgroups?

Yes.

The iDFS and dDFS improvements were seen across clinically important subgroups, including:

• Different anatomical stages
• Nodal status
• Prior endocrine therapy exposure

This suggests the benefit was not limited to one narrow patient group.

What About Overall Survival?

At the time of the 4-year update:

• Overall survival data were still immature.
• There was a trend toward benefit (HR 0.83).

However, because not enough events have occurred yet, firm conclusions about survival cannot be made.

A longer follow-up is needed to determine whether the reduction in recurrence ultimately translates into improved overall survival.

Safety Findings at 4 Years

An important question with a longer follow-up is whether new safety concerns emerge.

The researchers reported:

• No new safety signals.
• Serious adverse event rates were similar between arms:
  • 14.8% with ribociclib
  • 10.9% with NSAI alone

Dose Adjustments and Discontinuations

• 27.2% required ribociclib dose reduction.
• 23% dose reductions were due to adverse events.
• 20% discontinued ribociclib early due to side effects (similar to earlier analyses).

These discontinuation rates were consistent with previous reports.

Most Common Side Effects

Common all-grade adverse events in the ribociclib arm included:

• Neutropenia (low white blood cells)
• Arthralgia (joint pain)
• Nausea

Liver enzyme elevations (ALT/AST) were among the most common reasons for treatment discontinuation.

Overall, safety findings were consistent with prior analyses and with what is known about CDK4/6 inhibitors.

NATALEE 4-Year Results at a Glance

Key Results Summary

Outcome	Ribociclib + NSAI	NSAI Alone
4-Year iDFS	88.5%	83.6%
Absolute iDFS Benefit	+4.9%	—
iDFS Hazard Ratio	0.72	—
dDFS Hazard Ratio	0.72	—
RFS Hazard Ratio	0.70	—
Overall Survival	Trend toward benefit	—
New Safety Signals	None observed	—

Why This Update Is Important

One key concern with adjuvant therapy is whether the benefits persist after treatment ends.

In NATALEE:

• Ribociclib was given for 3 years.
• At 4 years, the recurrence reduction persisted.
• The absolute benefit increased over time.

This suggests that ribociclib may produce a lasting effect on reducing recurrence risk.

However, researchers emphasized that this was an exploratory analysis. Formal statistical testing was limited, and a longer follow-up is still needed.

What This Means for Patients

For patients with HR+/HER2– early breast cancer at risk of recurrence:

• Adding 3 years of Ribociclib to endocrine therapy reduced recurrence risk.
• The benefit continued after treatment completion.
• Safety remained consistent with previous data.

This strengthens the case for ribociclib as an adjuvant option in appropriate patients.

However, treatment decisions should consider:

• Individual recurrence risk
• Side effect tolerance
• Patient preferences
• Ongoing follow-up data

The Bigger Picture

Recurrence prevention remains one of the most important goals in early breast cancer treatment. Because distant recurrences are not curable, reducing even a few percentage points in recurrence risk can have a meaningful long-term impact.

The NATALEE 4-year follow-up shows:

• Sustained benefit beyond the 3-year ribociclib treatment period.
• Consistent reduction in invasive and distant recurrence.
• No new safety concerns.

A longer follow-up will clarify whether overall survival improves and how durable the benefit remains over time.

Conclusion

The updated 4-year analysis of the NATALEE trial answers an important question: Does ribociclib still help after 3 years of treatment?

Based on current data, the benefit appears to continue beyond treatment completion. Patients receiving ribociclib plus an aromatase inhibitor experienced fewer invasive and distant recurrences compared with endocrine therapy alone.

While overall survival data are still maturing, the sustained recurrence reduction represents a meaningful advance in adjuvant therapy for HR+/HER2– early breast cancer.

As follow-up continues, researchers will better understand the long-term impact of Ribociclib in preventing breast cancer recurrence.

References

1. JAMA Oncology (2025) – 4-Year Exploratory Analysis of the NATALEE Trial: Ribociclib Plus NSAI in HR+/ERBB2– Early Breast Cancer
2. New England Journal of Medicine (2024) – Primary Results of the NATALEE Trial: Adjuvant Ribociclib in HR+/HER2– Early Breast Cancer
3. Journal of Clinical Oncology (2023) – Second Interim Efficacy Analysis of NATALEE (LBA500)
4. Annals of Oncology (2025) – Updated Analysis of Ribociclib Plus Endocrine Therapy in Early Breast Cancer
5. MIMS Philippines News Update – NATALEE Updates: Ribociclib Benefit in HR+, ERBB2– EBC Sustained at 4 Years